FcRn’s promising features in cancer treatment and molecular diagnosis are rooted in its abilities of albumin recruitment [13,14] and the transcytosis of immunoglobulins, extending the half-life of cancer drugs and antibody-based therapeutics [15,16]. Here, FCGRT is linked to cancer.